CN1208063C - Chemical mixture and its use - Google Patents
Chemical mixture and its use Download PDFInfo
- Publication number
- CN1208063C CN1208063C CN 02135029 CN02135029A CN1208063C CN 1208063 C CN1208063 C CN 1208063C CN 02135029 CN02135029 CN 02135029 CN 02135029 A CN02135029 A CN 02135029A CN 1208063 C CN1208063 C CN 1208063C
- Authority
- CN
- China
- Prior art keywords
- chemical mixture
- pharmaceutical composition
- anisodamine
- moroxydine
- dexamethasone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 11
- 239000000126 substance Substances 0.000 title claims abstract 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract description 14
- WTQYWNWRJNXDEG-UHFFFAOYSA-N 6-Hydroxy-hyoscyamin Natural products CN1C(C2)CC(O)C1CC2OC(=O)C(CO)C1=CC=CC=C1 WTQYWNWRJNXDEG-UHFFFAOYSA-N 0.000 claims abstract description 7
- KJHOZAZQWVKILO-UHFFFAOYSA-N N-(diaminomethylidene)-4-morpholinecarboximidamide Chemical compound NC(N)=NC(=N)N1CCOCC1 KJHOZAZQWVKILO-UHFFFAOYSA-N 0.000 claims abstract description 7
- WTQYWNWRJNXDEG-LEOABGAYSA-N anisodamine Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@H]3[C@@H](O)C[C@@H](C2)N3C)=CC=CC=C1 WTQYWNWRJNXDEG-LEOABGAYSA-N 0.000 claims abstract description 7
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims abstract description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract description 7
- 229960003957 dexamethasone Drugs 0.000 claims abstract description 7
- 229960005389 moroxydine Drugs 0.000 claims abstract description 7
- 229960005489 paracetamol Drugs 0.000 claims abstract description 7
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 claims abstract description 7
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 206010022000 influenza Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 abstract description 6
- 206010041349 Somnolence Diseases 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 206010028372 Muscular weakness Diseases 0.000 abstract description 3
- 230000036473 myasthenia Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 206010067482 No adverse event Diseases 0.000 abstract 1
- 208000032140 Sleepiness Diseases 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229960003291 chlorphenamine Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a chemical mixture and a use thereof. The chemical mixture which is prepared by mixing five ingredients of paracetamol, moroxydine, anisodamine, dexamethasone and pseudoephedrine hydrochloride is applied to the drug treatment of cold to realize the advantages of good effect, no adverse reaction, such as somnolence, myasthenia of limb, etc., rapid effect, small side effect, economy and short treatment time.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, particularly a kind of pharmaceutical composition that can be used for treating flu.
Background technology
Flu is a kind of commonly encountered diseases, and almost everyone lives through the inconvenience that flu is brought.At present in tens kinds of coldrexs of selling on the market, indicate and contain the antihistaminic pharmaceutical compositions, account for about 70%.Contain antihistaminic pharmaceutical compositions (as chlorphenamine etc.) the caused untoward reaction of coldrex-dizziness, drowsiness, trick is aching and limp, myasthenia of limbs, though entail dangers to life not allows the people very uncomfortable also.Because drowsy, be unable to pull oneself together, have a strong impact on work, study, general two to three days ability of this situation is removed, many people fear to take this type of medicine that cures cold.Have the scholar to think: " chlorphenamine does not have therapeutic value to common cold.Its faint cholinolytic effect can reduce runny nose, but this kind desiccation is more harm than good.It causes does not drowsinessly have any benefit yet." (" Drug therapy preferred version " Zhang Annian writes the 332nd page of Chinese Medicine science and technology publishing house in March, 1999 front page).Though the coldrex of pure Chinese medicine preparation does not have the drowsiness untoward reaction of Denging, onset is slow comparatively speaking, and is unsatisfactory.
Summary of the invention
The purpose of this invention is to provide a kind of pharmaceutical composition, said composition can be very fast the healing flu, and safety, no untoward reaction such as drowsiness.
Pharmaceutical composition provided by the invention is made of by weight percentage following each composition:
Acetaminophen 63.3%-67.4%
Moroxydine 26.9%-31.5%
Anisodamine 1.0%-1.5%
Dexamethasone 0.2%
Pseudoephedrine hydrochloride 4%
More than the mechanism of action of each composition: acetaminophen can suppress the prostaglandin synthetase of human body, makes that prostaglandin is synthetic to be reduced and produce good antipyretic effect, can treat have a headache and fever, cold symptoms such as limbs pain, myalgia, general malaise.Moroxydine is a broad-spectrum antiviral drug, and RNA viruses (first type and Influenza B virus, parainfluenza virus, rhinovirus, respiratory syncytial virus) is all had the obvious suppression effect, is mainly used in and prevents and treats influenza, viral bronchitis etc.Anisodamine is the M cholinoreceptor blocker, can suppress lachrymal gland and respiratory tract glandular secretion, stops the watery nasal discharge that flu causes.Pseudoephedrine hydrochloride is an adrenomimetic, has the upper respiratory tract of contraction blood capillary, eliminates the nasopharynx part mucous hyperemia, alleviates the effect of nasal obstruction symptom.Dexamethasone is long lasting sugared skin parahormone class medicine, can suppress infectious and non-infectious inflammation, and it is synthetic to reduce the prostaglandin inflammatory mediator, alleviates the telangiectasis of nasopharynx inflam mation tissue and oozes out, and alleviates symptoms such as red, swollen, hot, pain.Can also reduce histamine release, the antagonism bacterial endotoxin is to the irritant reaction of body, and usefulness collaborative and the reinforcement said medicine.
Untoward reaction such as that pharmaceutical composition provided by the invention does not have is drowsiness, myasthenia of limbs, rapid-action, side effect is little, and economical and practical, and treatment time is short.
The specific embodiment:
Embodiment 1: get the pharmaceutical composition that is indication of the present invention after acetaminophen 63.3g, Moroxydine 26.9g, Anisodamine 1g, dexamethasone 0.2g, pseudoephedrine hydrochloride 4g mix.
Embodiment 2: get the pharmaceutical composition that is indication of the present invention after acetaminophen 67.4g, Moroxydine 31.5g, Anisodamine 1.5g, dexamethasone 0.2g, pseudoephedrine hydrochloride 4g mix.
Embodiment 3: get the pharmaceutical composition that is indication of the present invention after acetaminophen 65g, Moroxydine 28g, Anisodamine 1.25g, dexamethasone 0.2g, pseudoephedrine hydrochloride 4g mix.
Claims (1)
1. pharmaceutical composition that is used for the treatment of flu is characterized in that: said composition is that five kinds of chemical analysis by following each percentage by weight mix: acetaminophen 63.3%～67.4%, Moroxydine 26.9%～31.5%, Anisodamine 1.0%～1.5%, dexamethasone 0.2%, pseudoephedrine hydrochloride 4%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02135029 CN1208063C (en) | 2002-10-25 | 2002-10-25 | Chemical mixture and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02135029 CN1208063C (en) | 2002-10-25 | 2002-10-25 | Chemical mixture and its use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1491652A CN1491652A (en) | 2004-04-28 |
| CN1208063C true CN1208063C (en) | 2005-06-29 |
Family
ID=34231420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02135029 Expired - Lifetime CN1208063C (en) | 2002-10-25 | 2002-10-25 | Chemical mixture and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1208063C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1331485C (en) * | 2005-05-31 | 2007-08-15 | 王鹏程 | Medicine for treating cold |
| CN105412118B (en) * | 2015-12-17 | 2019-03-22 | 侯丽芳 | Treat dyspneic Western medicine compound of acute and chronic and preparation method thereof |
-
2002
- 2002-10-25 CN CN 02135029 patent/CN1208063C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1491652A (en) | 2004-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004518653A (en) | How to treat anxiety disorders | |
| BR0313718A (en) | Compound, process for the preparation thereof, pharmaceutical composition, methods for treating a human or animal subject suffering from a condition which is cox-2 mediated and for treating a human or animal subject suffering from an inflammatory disorder, and, use of a compound | |
| WO2003011327A3 (en) | Secretin for the treatment of asthma | |
| US20230233506A1 (en) | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker | |
| GB2430623A (en) | Medicaments for treating chronic respiratory disease | |
| CA2504872A1 (en) | Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections | |
| CN1208063C (en) | Chemical mixture and its use | |
| ATE326947T1 (en) | THIXOTROPIC NOSE SPRAY | |
| SI1407776T1 (en) | A pharmaceutical colloidal preparation comprising hyaluronic acid biopolymers useful in the treatment of respiratory diseases | |
| CA1169774A (en) | Medication having penetration through cutaneous surfaces into articular and muscular areas | |
| JP2012193159A (en) | Nasal spray | |
| Mendelson | Topical mafenide hydrochloride aqueous spray in initial management of massive contaminated wounds with devitalized tissue | |
| US5151415A (en) | Method of treating a papova-type viral infection | |
| BR0311180A (en) | Methods for treating respiratory diseases and conditions using a selective inhibitor of inos | |
| DE10340845A1 (en) | A combined pharmaceutical preparation containing glycyrrhizic acid, zinc and a compound containing a thiol group or a group metabolizable therewith | |
| EP1156830A2 (en) | Oil-in-water emulsion for the use as medicament or for producing a medicament | |
| JP2002030000A (en) | Fundamental treatment for common cold | |
| CN100558363C (en) | A kind of medicinal composition for treating condyloma acuminatum | |
| RU2009112724A (en) | CYCLIC SULPHONS AS MITOCHONDRIAL SODIUM-CALCIUM EXCHANGERS | |
| US20070032558A1 (en) | Method of treating herpes viral infections using a halogenated hydrocarbon composition | |
| CN118236433A (en) | A Miao medicine composition for treating tendinitis and its preparation method and application | |
| RU2577807C1 (en) | Cryogenic skin treatment method | |
| CN117899055A (en) | A kind of triptolide acupoint application suitable for rheumatoid arthritis | |
| SAKURANE et al. | Treatment of Verruca Plana Juvenilis with GammaGlobulin | |
| CN112773822A (en) | Pharmaceutical formulation for wound healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| AV01 | Patent right actively abandoned |
Granted publication date: 20050629 Effective date of abandoning: 20121226 |
|
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |